As an important proangiogenic factor, platelet-derived growth factor (PDGF) and its receptor PDGFR are highly expressed in a variety of tumors, fibrosis, cardiovascular and neurodegenerative diseases. Targeting the PDGF/PDGFR pathway is therefore a promising therapeutic strategy. At present, a variety of PDGF/PDGFR targeted drugs with potential therapeutic effects have been developed, mainly including PDGF agonists, inhibitors targeting PDGFR and proteolysis targeting chimera (PROTACs). This review clarifies the structure, biological function and disease correlation of PDGF and PDGFR, and it discusses the current status of PDGFR-targeted drugs, so as to provide a reference for subsequent research. Copyright © 2024 Elsevier Ltd. All rights reserved.
Jing-Yan Ai, Chen-Fu Liu, Wen Zhang, Guo-Wu Rao. Current status of drugs targeting PDGF/PDGFR. Drug discovery today. 2024 Jul;29(7):103989
PMID: 38663580
View Full Text